STOCK TITAN

Cathie Wood’s ARK Files 13G/A for 1.7M Arcturus Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Schedule 13G/A (Amendment 8) filed on 07/30/2025 discloses that ARK Investment Management LLC and its CEO/CIO Catherine D. Wood collectively hold a significant position in Arcturus Therapeutics Holdings Inc. (ARCT).

  • Shares beneficially owned: 1,715,040 common shares.
  • Ownership percentage: 6.32 % of ARCT’s outstanding stock.
  • Voting & dispositive power: ARK has sole voting and dispositive power over the full position; Wood has shared power through her control of ARK.
  • Form type of filer: ARK is an investment adviser (IA); Wood is reported as a holding-company/control person (HC, IN).
  • Client concentration: The ARK Genomic Revolution ETF is the only ARK client with an interest >5 % of ARCT.

The filing states the shares were acquired and are held in the ordinary course of business and not with the intent to influence control of the issuer.

Positive

  • ARK Investment Management and Catherine D. Wood disclose a 6.32 % stake (1.715 M shares) in ARCT, underscoring continued institutional ownership.

Negative

  • None.

Insights

TL;DR: ARK still owns 6.3 % of ARCT; disclosure is routine, confirming continued institutional backing without signaling strategy change.

The amendment shows ARK and Cathie Wood retain 1.72 M shares, equal to 6.32 % of the float—above the 5 % threshold that triggers a Schedule 13G filing. All voting and dispositive power resides with ARK, aligning with its role as investment adviser; Wood’s shared power reflects her control position. No new purchase or sale data is provided, so the filing is largely administrative. For investors, the key takeaway is that a high-profile growth-oriented manager remains a >5 % holder, which may be viewed as supportive of market perception but does not, on its own, alter ARCT’s fundamentals or near-term outlook.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



ARK Investment Management LLC
Signature:/s/ Kellen Carter
Name/Title:Kellen Carter, Chief Compliance Officer
Date:07/30/2025
Catherine D. Wood
Signature:/s/ Catherine D. Wood
Name/Title:Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
Date:07/30/2025

FAQ

How many Arcturus Therapeutics (ARCT) shares does ARK Investment Management own?

The filing reports 1,715,040 common shares beneficially owned.

What percentage of ARCT's outstanding stock is held by ARK and Cathie Wood?

They collectively own 6.32 % of the common shares.

Who are the reporting persons in the ARCT Schedule 13G/A?

The reporting persons are ARK Investment Management LLC and its CEO/CIO Catherine D. Wood.

What is the effective date of ownership stated in the filing?

The ownership information is stated as of June 30, 2025.

Does Catherine Wood have voting power over the ARCT shares?

Yes. Wood has shared voting and dispositive power over the 1.715 M shares through her control of ARK.

Why was a Schedule 13G/A filed for ARCT?

Because the reporting persons hold more than 5 % of ARCT’s outstanding shares, requiring disclosure under SEC Rule 13d-1.